Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $88.29

Keros Therapeutics, Inc. (NASDAQ:KROS) has received an average recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $92.17.

A number of research firms have recently weighed in on KROS. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Truist Financial reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Oppenheimer assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target for the company.

Keros Therapeutics Trading Up 1.5 %

Shares of KROS stock opened at $50.29 on Friday. Keros Therapeutics has a 1 year low of $27.02 and a 1 year high of $73.00. The firm’s 50 day moving average is $47.35 and its 200-day moving average is $55.38. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -9.77 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.12. The company had revenue of $0.08 million during the quarter. Keros Therapeutics’s revenue was down 97.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.26) EPS. On average, equities research analysts forecast that Keros Therapeutics will post -4.8 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. ADAR1 Capital Management LLC bought a new position in Keros Therapeutics during the 4th quarter worth approximately $27,367,000. Redmile Group LLC bought a new position in shares of Keros Therapeutics during the first quarter worth $36,576,000. Darwin Global Management Ltd. grew its holdings in shares of Keros Therapeutics by 35.4% in the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after buying an additional 375,523 shares during the period. Franklin Resources Inc. grew its holdings in shares of Keros Therapeutics by 47.9% in the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock valued at $27,809,000 after buying an additional 226,674 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Keros Therapeutics by 18.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company’s stock valued at $44,837,000 after buying an additional 222,652 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.